In Silico Approaches to Identify Polyphenol Compounds as α-Glucosidase and α-Amylase Inhibitors against Type-II Diabetes
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Type-II diabetes mellitus (T2DM) results from a combination of genetic and lifestyle factors, and the prevalence of T2DM is increasing worldwide. Clinically, both α-glucosidase and α-amylase enzymes inhibitors can suppress peaks of postprandial glucose with surplus adverse effects, leading to efforts devoted to urgently seeking new anti-diabetes drugs from natural sources for delayed starch digestion. This review attempts to explore 10 families e.g., Bignoniaceae, Ericaceae, Dryopteridaceae, Campanulaceae, Geraniaceae, Euphorbiaceae, Rubiaceae, Acanthaceae, Rutaceae, and Moraceae as medicinal plants, and folk and herb medicines for lowering blood glucose level, or alternative anti-diabetic natural products. Many natural products have been studied in silico, in vitro, and in vivo assays to restrain hyperglycemia. In addition, natural products, and particularly polyphenols, possess diverse structures for exploring them as inhibitors of α-glucosidase and α-amylase. Interestingly, an in silico discovery approach using natural compounds via virtual screening could directly target α-glucosidase and α-amylase enzymes through Monte Carto molecular modeling. Autodock, MOE-Dock, Biovia Discovery Studio, PyMOL, and Accelrys have been used to discover new candidates as inhibitors or activators. While docking score, binding energy (Kcal/mol), the number of hydrogen bonds, or interactions with critical amino acid residues have been taken into concerning the reliability of software for validation of enzymatic analysis, in vitro cell assay and in vivo animal tests are required to obtain leads, hits, and candidates in drug discovery and development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Fagerberg, L., Hallström, B. M., Oksvold, P., Kampf, C., Djureinovic, D., Odeberg, J., Habuka, M., Tahmasebpoor, S., Danielsson, A., Edlund, K., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.035600 · Cited by 3,665
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management
Chaudhury, A., Duvoor, C., Reddy Dendi, V. S., Kraleti, S., Chada, A., Ravilla, R., Marco, A., Shekhawat, N. S., Montales, M. T., Kuriakose, K., et al. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00006 · Cited by 1,500 · cited 1×
“A G protein-coupled receptors (GPCR) such as the GLP-1 receptor inhibitor blocks G protein (heterotrimeric) production (Table 1) [17].”
BackgroundType 2 Diabetes Mellitus: A Review of Current Trends
Olokoba, A. B., Obateru, O. A., & Olokoba, L. B. (2012) · Oman Medical Journal · doi:10.5001/omj.2012.68 · Cited by 1,338
Tyagi, S., Gupta, P., Saini, A., Kaushal, C., & Sharma, S. (2011) · Journal of Advanced Pharmaceutical Technology & Research · doi:10.4103/2231-4040.90879 · Cited by 1,017
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647 · cited 1×
“A healthy lifestyle and drug treatments are common practices in controlling blood glucose levels and delaying or preventing the occurrence of complications in T2DM patients [20].”
BackgroundHuang, S.-Y., Grinter, S. Z., & Zou, X. (2010) · Physical Chemistry Chemical Physics · doi:10.1039/c0cp00151a · Cited by 508 · cited 1×
“Moreover, a novel in silico study revealed a new class of triazoloquinazolines that are potent α-glucosidase inhibitors [252].”
BackgroundFerrannini, E. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.4.0336 · Cited by 451
Cited by
Mangifera indica L. Leaves as a Potential Food Source of Phenolic Compounds with Biological Activity
Sferrazzo, G., Palmeri, R., Restuccia, C., Parafati, L., Siracusa, L., Spampinato, M., Carota, G., Distefano, A., Di Rosa, M., Tomasello, B., et al. (2022) · Antioxidants · doi:10.3390/antiox11071313 · Cited by 31
Hu, J., Feng, Y., Li, B., Wang, F., Qian, Q., Tian, W., Niu, L., & Wang, X. (2023) · PeerJ · doi:10.7717/peerj.15948 · Cited by 6
“, 2020), polyphenols (Riyaphan et al., 2021), phytosterones (Gu et al.”
Metadata
- Authors
- Riyaphan, J., Pham, D.-C., Leong, M. K., & Weng, C.-F.
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2021-12-14
- Volume
- 11
- Issue
- 12
- Pages
- 1877
- ISSN
- 2218-273X (ISSN-L)
- OpenAlex
- W4200183983
- Cited by
- 162
- References
- 18
- FWCI
- 12.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In Silico Approaches to Identify Polyphenol Compounds as α-Glucosidase and α-Amylase Inhibitors against Type-II Diabetes. https://app.cochat.ai/papers/10.3390/biom11121877
- The paper
- Riyaphan, J., Pham, D.-C., Leong, M. K., & Weng, C.-F. (2021). In Silico Approaches to Identify Polyphenol Compounds as α-Glucosidase and α-Amylase Inhibitors against Type-II Diabetes. Biomolecules. https://doi.org/10.3390/biom11121877
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.